{"nctId":"NCT00109343","briefTitle":"V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)","startDateStruct":{"date":"2006-03"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":1027,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: ProQuad™ (V221)","Biological: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: ProQuad™ (V221)","Biological: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: ProQuad™ (V221)","Biological: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)"]}],"interventions":[{"name":"Comparator: ProQuad™ (V221)","otherNames":["ProQuad™","V221"]},{"name":"Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)","otherNames":["PREVNAR™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health\n* 12 to 15 months of age\n* Negative clinical history to measles, mumps, rubella, varicella and/or zoster\n* Received only the 3-dose primary series of a pneumococcal conjugate vaccine with at least 2 months prior to the receipt of any of the study vaccines\n* Signed consent\n\nExclusion Criteria:\n\n* Previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination\n* Any condition resulting in depressed immunity\n* Any allergy to any vaccine component as stated in the package circulars\n* Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination\n* History of seizure disorder\n* Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days\n* Recent febrile illness","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"15 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL","description":"Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\<255 mIU/mL) to Measles at Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null},{"groupId":"OG001","value":"203","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL","description":"Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\<10 ELISA Ab units/mL) to Mumps at Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL","description":"Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\<10 IU/mL) to Rubella at Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Varicella Antibody Titer ≥1.25 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL and ≥5 gpELISA Units/mL","description":"Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer \\<1.25 gpELISA units/mL at Baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"374","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"169","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 4","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 6B","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"408","spread":null},{"groupId":"OG001","value":"192","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 9V","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 14","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 18C","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"404","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 19F","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null},{"groupId":"OG001","value":"192","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 23F","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"412","spread":null},{"groupId":"OG001","value":"194","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 4 - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 4","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":null},{"groupId":"OG001","value":"1.34","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 6B - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 6B","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.17","spread":null},{"groupId":"OG001","value":"8.22","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 9V - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 9V","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":null},{"groupId":"OG001","value":"2.71","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 14 - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 14","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":null},{"groupId":"OG001","value":"5.61","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 18C - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 18C","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":null},{"groupId":"OG001","value":"2.23","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 19F - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 19F","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":null},{"groupId":"OG001","value":"3.22","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to S. Pneumoniae Serotype 23F - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 23F","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":null},{"groupId":"OG001","value":"3.71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":498},"commonTop":["Injection Site Pain (ProQuad Injection-site)","Pyrexia","Injection Site Erythema (ProQuad Injection-site)","Injection Site Swelling (ProQuad Injection-site)","Upper Respiratory Tract Infection"]}}}